ATOS — ATOSSA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1488039 ·
Last close
$4.95
Market Cap
$42.63M
52W High
$6.28
52W Low
$4.23
ADV30
53,652
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,870,000 | -9,589,000 | 37,943,000 | 31,718,000 | 7,457,000 |
| Dec 2025 | 0 | — | -11,436,000 | -10,937,000 | 47,608,000 | 41,299,000 | 8,255,000 |
| Sep 2025 | 0 | — | -9,251,000 | -8,692,000 | 58,012,000 | 51,845,000 | 8,225,000 |
| Jun 2025 | 0 | — | -9,040,000 | -8,423,000 | 64,515,000 | 57,857,000 | 6,820,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,762,000
Investing CF
$-23,000
Financing CF
$0
CapEx
$-33,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.75
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-246,562,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-37,141,000
Pretax Income TTM
$-34,770,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,141,000 | -34,770,000 | 47,608,000 | 8,255,000 | — | -29,762,000 |
| Dec 2024 | 0 | -27,621,000 | -25,504,000 | 76,444,000 | 4,967,000 | — | -21,030,000 |
| Dec 2023 | 0 | -31,377,000 | -30,094,000 | 96,252,000 | 5,236,000 | — | -20,941,000 |
| Dec 2022 | 0 | -27,691,000 | -26,960,000 | 123,532,000 | 5,568,000 | — | -20,760,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.44
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LTRN | Lantern Pharma Inc. | $43.12M | $3.38 | — |
| TLPH | TALPHERA, INC. | $41.52M | $0.80 | — |
| RNXT | RenovoRx, Inc. | $41.30M | $0.92 | — |
| PYRGF | PyroGenesis Canada Inc. | $44.26M | $0.21 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $40.93M | $0.97 | — |
News headlines (Yahoo Finance, 1h cache)
Atos Selected by Viasat to Modernize Global Digital Workplace Operations
2026-05-19 15:09 · Yahoo
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
2026-05-14 12:30 · Yahoo
ATOS: Initiating Coverage of Atossa Therapeutics; Endoxifen’s Expanding Opportunity from Oncology to Orphan Disease
2026-05-13 07:00 · Yahoo
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-08 12:45 · Yahoo
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
2026-05-06 12:30 · Yahoo
Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement
2026-05-05 14:49 · Yahoo
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
2026-05-04 12:30 · Yahoo
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service
2026-03-31 11:00 · Yahoo
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
2026-03-25 21:30 · Yahoo
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
2026-03-19 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.